It further states that while donanemab isn’t a cure for Alzheimer’s, it could become a valuable option for slowing the progression of the disease. In a major study, it was shown to help people with early Alzheimer’s maintain their memory, independence, and ability to do daily activities longer than those who didn’t take the drug. The benefits were greatest for those treated early in the disease.
Although there are some risks, like a low chance of certain side effects, the letter suggests these should be managed between patients and their doctors. Overall, it argues that donanemab could offer patients and their families more precious time and improved quality of life.